Prasco Laboratories has signed a distribution and supply agreement with Shire US Manufacturing, Inc. for mesalamine controlled-release capsules. Pending FDA approval, Prasco is prepared to market the generic version of Pentasa (mesalamine) Controlled-Release Capsules, at Shire’s request. The authorized generic will be marketed in the U.S. in 250 mg and 500 mg strengths under the Prasco label.

“We are excited to have established this new business relationship with Shire,” said Prasco chief executive officer, E. Thomas Arington.”Patients and pharmacists alike benefit when a company such as Shire commits to maintaining the supply of brand-identical medication through the Prasco Authorized Generic business model.”